Safeguarding patient welfare: who's in charge?

Ann Intern Med. 2006 Aug 15;145(4):305-7. doi: 10.7326/0003-4819-145-4-200608150-00013.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • Drug Industry*
  • Gabapentin
  • Humans
  • Legislation, Drug*
  • Marketing*
  • United States
  • United States Food and Drug Administration
  • gamma-Aminobutyric Acid

Substances

  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin